Amerikanische Gesellschaft für Hirudotherapie

Bivalirudin as an anticoagulation strategy for acute hemodialysis in children: Two cases with a summary of recent literature

Research article published in Hemodialysis international (2024)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportArzneimittelentwicklungViaene LV et al. · Hemodialysis international, 2024

Abstract

Unfractionated heparin is the most used anticoagulative agent for extracorporeal settings in children, including acute hemodialysis modalities. In certain situations, such as heparin-induced thrombocytopenia, alternatives must be applied. The direct thrombin inhibitor bivalirudin has come forth as an attractive substitute. Bivalirudin is currently only approved for adult use in specific percutaneous coronary intervention settings. However, it has a growing off-label popularity in different contexts for both adult and pediatric patients. Experience with bivalirudin in children is mainly limited to extracorporeal membrane oxygenation, ventricular assist devices and during cardiopulmonary bypass surgery. Literature about its use as anticoagulation strategy for pediatric hemodialysis is very scarce. Here, we present two pediatric cases where bivalirudin was used during acute hemodialysis, followed by a short summary of recent literature.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase ReportsReview
Indexed MeSH termsHumansHirudinsRecombinant ProteinsRenal DialysisPeptide FragmentsAnticoagulantsMaleFemaleChildAdolescentChild, PreschoolAntithrombins

Zusammenfassung

Bivalirudin as an anticoagulation strategy for acute hemodialysis in children: Two cases with a summary of recent literature.

Warum dies für die Hirudotherapie relevant ist

This paper presents two pediatric case reports using bivalirudin, described in the abstract as a direct thrombin inhibitor, as an alternative anticoagulant for acute hemodialysis when unfractionated heparin is contraindicated, such as in heparin-induced thrombocytopenia, accompanied by a summary of recent literature. The abstract makes no mention of hirudin, leeches, or any relationship to hirudotherapy. Therefore, no defensible leech or ASH connection can be drawn from this abstract alone. The clinical data is limited to two cases plus a brief literature summary, serving as an anecdotal report of off-label usage rather than robust safety or efficacy evidence.

Zitation

Bivalirudin as an anticoagulation strategy for acute hemodialysis in children: Two cases with a summary of recent literature

Viaene LV et al. · Hemodialysis international, 2024

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.